Datopotamab Deruxtecan Improved Progression-Free Survival Ve

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Oct 23, 2023--

Related Keywords

United States , Tokyo , Japan , Sapporo , Hokkaido , American , America , Susan Galbraith , Aaron Lisberg , Daiichi Sankyo , Jennifer Brennan , Datopotamab Deruxtecan , Ann Onc , Koji Ogiwara , Ken Takeshita , Anticancer Research , Daiichi Sankyo Co Ltd , World Health Organization , Nasdaq , Sapporo Medical University , Daiichi Sankyo Inc , European Society For Medical Oncology , Astrazeneca , National Cancer Institute , International Agency For Research On Cancer , American Cancer Society , Merck Co Inc , Presidential Symposium , European Society , Medical Oncology , Median Dor , Thoracic Medical Oncology , Global Head , Executive Vice President , North America , Statistics Factsheets , Bronchus Cancer , International Agency , Lung Fact , Accessed October , Targeted Drug Therapy , Non Small Cell Lung , Investor Relations , Business Wire , Business ,